Diabetes Technology Use for Management of Type 1 Diabetes Is Associated With Fewer Adverse COVID-19 Outcomes: Findings From the T1D Exchange COVID-19 Surveillance Registry

Nudrat Noor; Osagie Ebekozien; Laura Levin; Sheri Stone; David P. Sparling; Robert Rapaport; David M. Maahs

doi:10.2337/DC21-0074

Diabetes Technology Use for Management of Type 1 Diabetes Is Associated With Fewer Adverse COVID-19 Outcomes: Findings From the T1D Exchange COVID-19 Surveillance Registry

Nudrat Noor, Osagie Ebekozien, Laura Levin, Sheri Stone, David P. Sparling, Robert Rapaport, David M. Maahs

Icahn School of Medicine at Mount Sinai

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Original language	English
Pages (from-to)	e160-e162
Journal	Diabetes Care
Volume	44
Issue number	8
DOIs	https://doi.org/10.2337/DC21-0074
State	Published - Aug 2021

Access to Document

10.2337/DC21-0074

Cite this

@article{57b538a43b39417e96d5cc3009a25110,

title = "Diabetes Technology Use for Management of Type 1 Diabetes Is Associated With Fewer Adverse COVID-19 Outcomes: Findings From the T1D Exchange COVID-19 Surveillance Registry",

author = "Nudrat Noor and Osagie Ebekozien and Laura Levin and Sheri Stone and Sparling, {David P.} and Robert Rapaport and Maahs, {David M.}",

note = "Funding Information: lead coinvestigators in the T1DX COVID-19 Surveillance study. The authors also appreciate Saketh Rompicherla (T1D Exchange) for his help with data analysis and coordination. The authors are grateful to the >50 participating centers contributing data to this project. The list of participating hospitals and investigators can be found at www.t1dexchange.org/COVID19. Funding. T1D Exchange received financial support for COVID-19 response from JDRF. The Leona M. and Harry B. Helmsley Charitable Trust funds the T1D Exchange QI and Population Health Program that coordinated this study. D.M.M. is supported by National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), grant P30DK116074. D.M.M. has had research support from the NIH, JDRF, National Science Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust. D.M.M. has consulted for the Leona M. and Harry B. Helms-ley Charitable Trust. Duality of Interest. T1D Exchange also received financial support for COVID-19 response from Dexcom, Medtronic, Eli Lilly, Abbot, and Insulet. O.E. is the principal investigator for different investigator-led research projects funded by Medtronic and Eli Lilly. O.E. is a member of the Medtronic Diabetes Health Inequity Board. D.M.M.{\textquoteright}s institution has had research support from Medtronic, Dexcom, Insulet, Bigfoot Biomedical, Tandem, and Roche. D.M.M. has consulted for Abbott, Aditx Therapeutics, Sanofi, Novo Nordisk, Eli Lilly, Medtronic, Insulet, and Domp{\'e}. No other potential conflicts of interest relevant to this article were reported. Author Contributions. N.N. and O.E. conceptualized the study. N.N. wrote the draft of the manuscript and analyzed the data. All authors critically reviewed the manuscript and approved the final version. N.N is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.",

year = "2021",

month = aug,

doi = "10.2337/DC21-0074",

language = "English",

volume = "44",

pages = "e160--e162",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association Inc.",

number = "8",

}

TY - JOUR

T1 - Diabetes Technology Use for Management of Type 1 Diabetes Is Associated With Fewer Adverse COVID-19 Outcomes

T2 - Findings From the T1D Exchange COVID-19 Surveillance Registry

AU - Noor, Nudrat

AU - Ebekozien, Osagie

AU - Levin, Laura

AU - Stone, Sheri

AU - Sparling, David P.

AU - Rapaport, Robert

AU - Maahs, David M.

N1 - Funding Information: lead coinvestigators in the T1DX COVID-19 Surveillance study. The authors also appreciate Saketh Rompicherla (T1D Exchange) for his help with data analysis and coordination. The authors are grateful to the >50 participating centers contributing data to this project. The list of participating hospitals and investigators can be found at www.t1dexchange.org/COVID19. Funding. T1D Exchange received financial support for COVID-19 response from JDRF. The Leona M. and Harry B. Helmsley Charitable Trust funds the T1D Exchange QI and Population Health Program that coordinated this study. D.M.M. is supported by National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), grant P30DK116074. D.M.M. has had research support from the NIH, JDRF, National Science Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust. D.M.M. has consulted for the Leona M. and Harry B. Helms-ley Charitable Trust. Duality of Interest. T1D Exchange also received financial support for COVID-19 response from Dexcom, Medtronic, Eli Lilly, Abbot, and Insulet. O.E. is the principal investigator for different investigator-led research projects funded by Medtronic and Eli Lilly. O.E. is a member of the Medtronic Diabetes Health Inequity Board. D.M.M.’s institution has had research support from Medtronic, Dexcom, Insulet, Bigfoot Biomedical, Tandem, and Roche. D.M.M. has consulted for Abbott, Aditx Therapeutics, Sanofi, Novo Nordisk, Eli Lilly, Medtronic, Insulet, and Dompé. No other potential conflicts of interest relevant to this article were reported. Author Contributions. N.N. and O.E. conceptualized the study. N.N. wrote the draft of the manuscript and analyzed the data. All authors critically reviewed the manuscript and approved the final version. N.N is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

PY - 2021/8

Y1 - 2021/8

UR - http://www.scopus.com/inward/record.url?scp=85114088484&partnerID=8YFLogxK

U2 - 10.2337/DC21-0074

DO - 10.2337/DC21-0074

M3 - Article

C2 - 34385347

AN - SCOPUS:85114088484

SN - 0149-5992

VL - 44

SP - e160-e162

JO - Diabetes Care

JF - Diabetes Care

IS - 8

ER -